Bruce Culliney, MD

Clinical Focus

• Head and Neck Cancers

• Head and Neck Cancers

Research

Locations

Mount Sinai Union Square

10 Union Square East, Suite 3H, New York, NY, 10003

212-844-8288

The Blavatnik Family – Chelsea Medical Center

325 West 15th Street, 1st Floor, (between 8th and 9th Avenues), New York, NY, 10011

212-844-8288

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:13

Article:14

Review Article:4

Chapter:1

Recent Artifacts

• Tracheostomy during SARS-CoV-2 pandemic: Recommendations from the New York Head and Neck Society
• Head and neck cancer
• Objective and subjective hyposalivation after treatment for head and neck cancer: Long-term outcomes
• Low rates of contralateral neck failure in unilaterally treated oropharyngeal squamous cell carcinoma with prospectively defined criteria of lateralization
• Five-year outcomes of an oropharynx-directed treatment approach for unknown primary of the head and neck
• Long-term outcomes and patterns of failure in orbital lymphoma treated with primary radiotherapy
• Postoperative radiation therapy for parotid pleomorphic adenoma with close or positive margins: Treatment outcomes and toxicities
• Functional outcomes and quality of life after chemoradiotherapy: Baseline and 3 and 6 months post-treatment
• Five-year outcomes of squamous cell carcinoma of the tonsil treated with radiotherapy
• Initial experience with oropharynx-targeted radiation therapy for metastatic squamous cell carcinoma of unknown primary of the head and neck

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Culliney did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.